Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: Cancer J Clin. 2024;74:229–63.

Kratzer TB, Bandi P, Freedman ND, Smith RA, Travis WD, Jemal A, et al. Lung cancer statistics, 2023. Cancer. 2024;130:1330–48.

Article  PubMed  Google Scholar 

Lam S, Bai C, Baldwin DR, Chen Y, Connolly C, de Koning H, et al. Current and future perspectives on computed tomography screening for lung cancer: a roadmap from 2023 to 2027 from the international association for the study of lung cancer. J Thorac Oncol. 2024;19:36–51.

Article  PubMed  Google Scholar 

Tanoue LT, Tanner NT, Gould MK, Silvestri GA. Lung cancer screening. Am J Respir Crit Care Med. 2015;191:19–33.

Article  PubMed  Google Scholar 

Veronesi G, Maisonneuve P, Bellomi M, Rampinelli C, Durli I, Bertolotti R, et al. Estimating overdiagnosis in low-dose computed tomography screening for lung cancer: a cohort study. Ann Intern Med. 2012;157:776–84.

Article  PubMed  Google Scholar 

Gao W, Wen CP, Wu A, Welch HG. Association of computed tomographic screening promotion with lung cancer overdiagnosis among asian women. JAMA Intern Med. 2022;182:283–90.

Article  PubMed  Google Scholar 

Patz EF, Pinsky P, Gatsonis C, Sicks JD, Kramer BS, Tammemägi MC, et al. Overdiagnosis in low-dose computed tomography screening for lung cancer. JAMA Intern Med. 2014;174:269–74.

Article  PubMed  PubMed Central  Google Scholar 

Bruno H, Volkert S, John B. Estimation of overdiagnosis of lung cancer in low-dose computed tomography screening. Jama Internal Med. 2018;178:1420-2.

da Cunha Santos G, Shepherd FA, Tsao MS. EGFR mutations and lung cancer. Annu Rev Pathol. 2011;6:49–69.

Article  PubMed  Google Scholar 

D’Angelo SP, Pietanza MC, Johnson ML, Riely GJ, Miller VA, Sima CS, et al. Incidence of EGFR exon 19 deletions and L858R in tumor specimens from men and cigarette smokers with lung adenocarcinomas. J Clin Oncol. 2011;29:2066–70.

Article  PubMed  PubMed Central  Google Scholar 

Ahn M-J, Han J-Y, Lee KH, Kim S-W, Kim D-W, Lee Y-G, et al. Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1-2 study. Lancet Oncol. 2019;20:1681–90.

Article  PubMed  Google Scholar 

Wu Y-L, Zhong W-Z, Li L-Y, Zhang X-T, Zhang L, Zhou C-C, et al. Epidermal growth factor receptor mutations and their correlation with gefitinib therapy in patients with non-small cell lung cancer: a meta-analysis based on updated individual patient data from six medical centers in mainland China. J Thorac Oncol. 2007;2:430–9.

Article  PubMed  Google Scholar 

Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012;13:239–46.

Article  PubMed  Google Scholar 

Duggirala KB, Lee Y, Lee K. Chronicles of EGFR Tyrosine Kinase Inhibitors: targeting EGFR C797S Containing Triple Mutations. Biomol Ther. 2022;30:19–27.

Article  Google Scholar 

Zhong W-Z, Chen K-N, Chen C, Gu C-D, Wang J, Yang X-N, et al. Erlotinib versus gemcitabine plus cisplatin as neoadjuvant treatment of stage IIIA-N2 EGFR-mutant non-small-cell lung cancer (EMERGING-CTONG 1103): a randomized phase II study. J Clin Oncol. 2019;37:2235–45.

Article  PubMed  Google Scholar 

Cho BC, Chewaskulyong B, Lee KH, Dechaphunkul A, Sriuranpong V, Imamura F et al. Osimertinib versus standard-of-care EGFR-TKI as first-line treatment in patients with EGFRm advanced NSCLC: FLAURA Asian subset. J Thorac Oncol. 2018;14:99–106.

Planchard D, Jnne PA. Investigators CYJC-HNS-WSYYSLKCKNSJ-MIJDYAKtF. Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC. N Engl J Med. 2023;389:1935–48.

Article  PubMed  Google Scholar 

Felip E, Cho BC, Gutiérrez V, Alip A, Besse B, Lu S, et al. Amivantamab plus lazertinib vs osimertinib in first-lineEGFR-mutant advanced non-small cell lung cancer (NSCLC) with biomarkers of high-risk disease: a secondary analysis from the phase 3 MARIPOSA study. J Clin Oncol. 2024;42:8504.

Article  Google Scholar 

Voldborg BR, Damstrup L, Spang-Thomsen M, Poulsen HS. Epidermal growth factor receptor (EGFR) and EGFR mutations, function and possible role in clinical trials. Ann Oncol. 1997;8:1197–206.

Article  PubMed  Google Scholar 

Cortés-Sempere M, de Miguel MP, Pernía O, Rodriguez C, de Castro Carpeño J, Nistal M, et al. IGFBP-3 methylation-derived deficiency mediates the resistance to cisplatin through the activation of the IGFIR/Akt pathway in non-small cell lung cancer. Oncogene. 2013;32:1274–83.

Article  PubMed  Google Scholar 

Liu Q, Yu S, Zhao W, Qin S, Chu Q, Wu K. EGFR-TKIs resistance via EGFR-independent signaling pathways. Mol Cancer. 2018;17:53.

Article  PubMed  PubMed Central  Google Scholar 

Salnikow K, Davidson T, Zhang Q, Chen LC, Su W, Costa M. The involvement of hypoxia-inducible transcription factor-1-dependent pathway in nickel carcinogenesis. Cancer Res. 2003;63:3524–30.

PubMed  Google Scholar 

Zhong H, De Marzo AM, Laughner E, Lim M, Hilton DA, Zagzag D et al. Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res. 1999;59:5830–5.

Cangul H. Hypoxia upregulates the expression of the NDRG1 gene leading to its overexpression in various human cancers. BMC Genet. 2004;5:27.

Article  PubMed  PubMed Central  Google Scholar 

Jung EU, Yoon J-H, Lee Y-J, Lee J-H, Kim BH, Yu SJ, et al. Hypoxia and retinoic acid-inducible NDRG1 expression is responsible for doxorubicin and retinoic acid resistance in hepatocellular carcinoma cells. Cancer Lett. 2010;298:9–15.

Article  PubMed  Google Scholar 

Huang Y-T, Liu C-H, Yang Y-C, Aneja R, Wen S-Y, Huang C-Y, et al. ROS- and HIF1α-dependent IGFBP3 upregulation blocks IGF1 survival signaling and thereby mediates high-glucose-induced cardiomyocyte apoptosis. J Cell Physiol. 2019;234:13557–70.

Article  PubMed  Google Scholar 

Wen S-Y, Ali A, Huang I-C, Liu J-S, Chen P-Y, Padma Viswanadha V, et al. Doxorubicin induced ROS-dependent HIF1α activation mediates blockage of IGF1R survival signaling by IGFBP3 promotes cardiac apoptosis. Aging. 2023;15:164–78.

Article  PubMed  PubMed Central  Google Scholar 

Wu E-H, Li H-S, Zhao T, Fan J-D, Ma X, Xiong L, et al. Effect of hypoxia on the gene profile of human bone marrow-derived mesenchymal stem cells]. Sheng Li Xue Bao: [Acta Physiologica Sin]. 2007;59:227–32.

PubMed  Google Scholar 

Kovacevic Z, Menezes SV, Sahni S, Kalinowski DS, Bae D-H, Lane DJR, et al. The metastasis suppressor, N-MYC downstream-regulated Gene-1 (NDRG1), down-regulates the ErbB family of receptors to inhibit downstream oncogenic signaling pathways. J Biol Chem. 2016;291:1029–52.

Article  PubMed  Google Scholar 

Chekmarev J, Azad MG, Richardson DR. The oncogenic signaling disruptor, NDRG1: molecular and cellular mechanisms of activity. Cells. 2021;10:2382.

Article  PubMed  PubMed Central  Google Scholar 

Fan X, Wang Y, Jiang T, Cai W, Jin Y, Niu Y, et al. B-Myb mediates proliferation and migration of non-small-cell lung cancer via suppressing IGFBP3. Int J Mol Sci. 2018;19:1479.

Article  PubMed  PubMed Central  Google Scholar 

Kuhn H, Frille A, Petersen MA, Oberhuber-Kurth J, Hofmann L, Gläser A, et al. IGFBP3 inhibits tumor growth and invasion of lung cancer cells and is associated with improved survival in lung cancer patients. Transl Oncol. 2023;27:101566.

Article  PubMed  Google Scholar 

Wang YA, Sun Y, Palmer J, Solomides C, Huang LC, Shyr Y, et al. IGFBP3 modulates lung tumorigenesis and cell growth through IGF1 signaling. Mol Cancer Res. 2017;15:896–904.

Hong J, Won M, Ro H. The molecular and pathophysiological functions of members of the LNX/PDZRN E3 Ubiquitin ligase family. Molecules. 2020;25:5938.

Article  PubMed  PubMed Central  Google Scholar 

Katoh M, Katoh M. Identification and characterization of PDZRN3 and PDZRN4 genes in silico. Int J Mol Med. 2004;13:607–13.

PubMed  Google Scholar 

Jin P, Wu L, Zhang G, Yang B, Zhu B. PDZRN4 suppresses tumorigenesis and androgen therapy-resistance in prostate cancer. J Cancer. 2022;13:2293–300.

Article  PubMed  PubMed Central  Google Scholar 

Lu Y-L, Yang X, Liu Y-K. Reduced PDZRN4 promotes breast cancer progression and predicts poor prognosis. Int J Clin Exp Pathol. 2019;12:142–53.

PubMed  PubMed Central  Google Scholar 

Hu T, Yang H, Han ZG. PDZRN4 acts as a suppressor of cell proliferation in human liver cancer cell lines. Cell Biochem Funct. 2015;33:443–9.

Article  PubMed  Google Scholar 

Liu X, Xing C. PDZRN4-mediated colon cancer cell proliferation and dissemination is regulated by miR-221-3p. Transl Cancer Res. 2019;8:1289–300.